Tyroserleutide hydrochloride

Research use only, not for human use.

Tyroserleutide hydrochloride is a small molecule tripeptide isolated from the degradation product of pig spleen, which can inhibit tumor growth in vivo and in vitro.

Tyroserleutide hydrochloride is a small molecule tripeptide isolated from the degradation product of pig spleen, which can inhibit tumor growth in vivo and in vitro.(In Vitro):Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells. Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression. Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells. Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration.(In Vivo):Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice.

Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells.Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression. Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells. Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration.

Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice. Animal Model:Female Kun-Ming mice (18-22 g, 6 week old) with H22 tumor modelDosage:10, 20, 40, and 80 μg/kg Administration:Injection (i.p.) one time every day until mice were dead. Result:Survival times are 25.53±14.14, 25.82±14.29, 30.47±17.89, 35.06±20.90 days for 10, 20, 40, and 80 μg/kg, respectively.

——

Others

Other Targets

Antitumor tripeptide

——

——

852982-42-4

417.88

C18H28ClN3O6

>98% (HPLC)

DMSO : 250 mg/mL (598.26 mM; Need ultrasonic)

——

——

(-20℃)

With Ice Pack

≥ 2 years